文献速递头颈外科

老年口咽癌的治疗、生存与费用分析

Treatment, survival, and costs of oropharyngeal cancer care in the elderly.
PubMed 文献 · Laryngoscope · 2017-10-08

该回顾性横断面分析基于SEER-Medicare数据,纳入2004至2007年诊断的666例老年口咽鳞状细胞癌患者。研究发现手术加术后放疗(HR 0.33)和放化疗(HR 0.45)与生存改善相关,IV期疾病与生存较差相关(HR 1.95)。放化疗后更可能需要额外抗癌治疗(OR 3.44), salvage手术集中于高容量医院(OR 2.81),且初始治疗6个月后进行的额外放疗(HR 0.47)和salvage手术(HR 0.61)与总生存改善相关。

要点

  • 手术加术后放疗和放化疗与老年口咽癌患者生存改善相关。
  • 放化疗后需要额外抗癌治疗的可能性更高。
  • Salvage手术在高容量医院进行,且初始治疗6个月后实施与生存改善相关。

核心结论

  • 多模式治疗与老年口咽癌患者生存改善相关,但费用增加。
  • 放化疗与额外抗癌治疗可能性增加相关。
  • Salvage手术集中于高容量医院,且在初始治疗6个月后实施与生存改善相关。

研究设计与样本

  • 回顾性横断面分析,使用SEER-Medicare数据,纳入666例2004至2007年诊断的口咽鳞状细胞癌患者。

主要发现

  • 多数患者为非吸烟者(79%),晚期疾病(59%),接受放化疗(38%)或放疗(28%)。
  • 手术加术后放疗(HR 0.33,95%CI 0.20-0.53)和放化疗(HR 0.45,95%CI 0.29-0.71)与生存改善相关。
  • IV期疾病与生存较差相关(HR 1.95,95%CI 1.13-3.38)。
  • 放化疗后额外抗癌治疗可能性更高(OR 3.44,95%CI 1.78-6.63)。
  • 25%接受后续额外抗癌治疗的患者进行了salvage手术,与高容量医院相关(OR 2.81,95%CI 1.07-7.74)。

关键数值与推荐

  • 初始治疗6个月后额外放疗(HR 0.47,95%CI 0.31-0.72)和salvage手术(HR 0.61,95%CI 0.38-0.99)与总生存改善相关。
  • 单独salvage颈清扫在控制salvage时间后与生存无显著相关(HR 0.38,95%CI 0.05-2.78)。
  • 治疗和5年总费用在放化疗、手术加术后放疗和额外抗癌治疗中最高。

临床怎么用

  • 老年口咽癌患者可考虑多模式治疗以改善生存,但需权衡费用。
  • 放化疗后应警惕额外抗癌治疗的需求。
  • Salvage手术可能受益于高容量医院,且初始治疗6个月后实施与生存改善相关。

局限性

  • 回顾性研究设计。
  • 基于SEER-Medicare数据,可能限于老年医保人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To examine associations between treatment, survival, and costs in elderly patients with oropharyngeal squamous cell cancer (OPSCC). STUDY DESIGN: Retrospective cross-sectional analysis of Surveillance, Epidemiology, and End Results-Medicare data. METHODS: We evaluated 666 patients diagnosed with OPSCC from 2004 to 2007 using cross-tabulations, multivariate logistic and generalized linear regression modeling, and survival analysis. RESULTS: The majority of patients were nonsmokers (79%), had advanced-stage disease (59%), and received chemoradiation (38%) or radiation (28%). Surgery with postoperative radiation (hazard ratio [HR]: 0.33 [95% CI: 0.20-0.53]) and chemoradiation (HR: 0.45 [95% CI: 0.29-0.71]) were associated with improved survival, whereas stage IV disease was associated with poorer survival (HR: 1.95 [95% CI: 1.13-3.38]). Additional cancer-directed treatment after primary treatment was more likely following chemoradiation (odds ratio [OR]: 3.44 [95% CI: 1.78-6.63]). Salvage surgery was performed in 25% of patients undergoing subsequent additional cancer-directed treatment, and was associated with high-volume hospitals (OR: 2.81 [95% CI: 1.07-7.74]). Additional radiation (HR: 0.47 [95% CI: 0.31-0.72]) and salvage surgery (HR: 0.61 [95% CI: 0.38-0.99]) were associated with improved overall survival when performed >6 months following initial treatment, whereas salvage neck dissection alone was not significantly associated with survival after controlling for time to salvage (HR: 0.38 [95% CI: 0.05-2.78]). Treatment and 5-year overall costs were highest for chemoradiation, surgery with postoperative radiation, and additional cancer-directed treatment. CONCLUSIONS: Multimodality treatment in elderly OPSCC patients was associated with improved survival and increased costs. Chemoradiation was associated with an increased likelihood of additional cancer-directed treatment. Salvage surgery was centralized at high-volume hospitals, and was associated with improved survival when performed >6 months after last initial treatment date, but was performed in <20% of patients undergoing additional treatment. LEVEL OF EVIDENCE: 2c. Laryngoscope, 128:1103-1112, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Gourin CG, Fakhry C, Quon H, et al. Treatment, survival, and costs of oropharyngeal cancer care in the elderly. Laryngoscope. 2017. PMID: 28988469. doi:10.1002/lary.26887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。